0001209191-23-037208.txt : 20230614
0001209191-23-037208.hdr.sgml : 20230614
20230614201805
ACCESSION NUMBER: 0001209191-23-037208
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230612
FILED AS OF DATE: 20230614
DATE AS OF CHANGE: 20230614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Novo Holdings A/S
CENTRAL INDEX KEY: 0001388325
STATE OF INCORPORATION: G7
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40499
FILM NUMBER: 231015758
BUSINESS ADDRESS:
STREET 1: TUBORG HAVNEVEJ 19
CITY: HELLERUP
STATE: G7
ZIP: 2900
BUSINESS PHONE: 45 8824 8824
MAIL ADDRESS:
STREET 1: TUBORG HAVNEVEJ 19
CITY: HELLERUP
STATE: G7
ZIP: 2900
FORMER NAME:
FORMER CONFORMED NAME: Novo A/S
DATE OF NAME CHANGE: 20070130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cyteir Therapeutics, Inc.
CENTRAL INDEX KEY: 0001662244
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 455429901
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HAYDEN AVENUE
STREET 2: BUILDING B, SUITE 450
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 857-285-4140
MAIL ADDRESS:
STREET 1: 99 HAYDEN AVENUE
STREET 2: BUILDING B, SUITE 450
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-12
0
0001662244
Cyteir Therapeutics, Inc.
CYT
0001388325
Novo Holdings A/S
TUBORG HAVNEVEJ 19
HELLERUP
G7
2900
DENMARK
0
0
1
0
0
Common Stock
2023-06-12
4
S
0
900
2.0645
D
3939513
D
Common Stock
2023-06-13
4
S
0
2626
2.10
D
3936887
D
Common Stock
2023-06-14
4
S
0
2872
2.1066
D
3934015
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.03 to $2.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.06 to $2.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.03 to $2.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
/s/ Barbara Fiorini Due, General Counsel, Finance & Operations of Novo Holdings A/S
2023-06-14